The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Preoperative CRT improves overall survival in pancreatic cancer: long-term results of PREOPANC
Casper H. Van Eijck, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, discusses the long-term results of a multicenter, randomized, Phase III trial evaluating preoperative chemoradiotherapy (CRT) in patients with resectable and borderline resectable pancreatic cancer. Preoperative gemictabine-based chemoradiation for pancreatic cancer demonstrated improved long-term overal survival when compared to immediate surgery with adjuvant gemcitabine. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
